KRONİK MİYELOSİTER LÖSEMİ Prof. Dr. Osman İlhan A.Ü.T.F. İbni ...

KAYNAKLAR
1- Wintrobe’s Clinical Hematology. Eds: Greer JP,Rodgers GM, Foerster J, Paraskevas
F, Lukens JN and Glader B. 11rd Ed. Lipincott Williams&Wilkins, 2004
2- Nowell PC and Hungerford DA. A minutes chromosome in human granulocyte
leukemia. Science 1960, 132: 1497
3- Bernstein R. Cytogenetics of chronic myelogenous leukemia. Semin Hematol 1988,
25: 20-34
4- Melo JV, Hughes TP and Apperley JF. Chronic myeloid leukemia. ASH education
book, 2003, 132-152
5- Hoffman R, editors, Hematology, Basic Principles and Practice, 3rd Edition,
Pennsylvania, Churchill Livingstone, 2000
6- Silver RT, Woolf SH, Hehlmann R ve ark. An evidence based analysis of the effect of
busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in
treating the chronic phase of chronic myeloid leukemia: Developed for the American
Society of Hematology. Blood 94:1517, 1999
7- Barrett J. Allogeneic stem cell transplantation for chronic myeloid leukemia. Semin
Hematol 2003, 40:59-71
8- Maziarz R and Mauro MJ. Transplantation for chronic myelogenous leukemia: yes,
no, maybe so… an Oregon perspective. Bone Marrow Transplant 2003, 23: 459-469
9- Sardas OS, Koc H, Beksac M. Interferon-alpha2b therapy and monitorization of serum
IL-2R, TNF, G-CSF and GM-CSF in chronic myelogenous leukemia. Eur J Cancer,
1991 Suppl 2, 1380
10- Ozer H, George SL, Schiffer CA, et al. Prolonged subcutaneous administration of
recombinant alpha2b interferon in patients with previously untreated Philedelphia
chromosome-positive chronic phase chronic myelogenous leukemia: effect on
remission duration and survival: Cancer and Leukemia Group B Study 8583. Blood
1993, 82: 2975-2984
11- Kantarjian M, Smith TL, O’Brien S ve ark. Prolonged survival in chronic
myelogeneous leukemia after cytogenetic response to interferon alpha therapy. Ann
Intern Med 122:254, 1995
12- Chronic myeloid leukemia trialist’s collaborative group: Interferon alfa vs
chemotherapy for chronic myeloid leukemia: A meta-analysis of seven randomized
trials. J Natl Cancer Inst 89:1616, 1997
13- Sokal JE, Cox EB, Baccarani N, ve ark. Prognostic discrimination in good-risk
chronic granulocytic leukemia. Blood 1984, 63:789-799
14- Hasford J, Pfirmann M, Hehlmann R ve ark. A new prognostic score for survival of
patients with CML treated with IFNa. J Natl Canc Inst 1998, 90:850-858
15- Kantarjian HM, O’Brien S, Smith TL, et al. Treatment of Philedelphia chromosome
positive early chronic phase chronic myelogenous leukemia with daily doses of
interferon alpha and low dose cytarabine. J Clin Oncol 1999, 17: 284-292
16- Guilhot F, Chastang C, Michallet M et al. IFNa 2b combined with cytarabine versus
interferon alone in chronic myelogeneous leukemia. French Chronic Leukemia Study
Group. N Engl J Med 337:223, 1997.
17- Baccarani M, Rosti G, de Vivo A, et al. Italian Cooperative Study Group on Myeloid
Leukemia. A randomized study of interferon-alpha and low-dose arabinosyl cytosine
in chronic myeloid leukemia. Blood 2002, 99: 1527-1535.